We are live on ! Find out more
BRTX icon

BioRestorative Therapies
BRTX

14 hedge funds and large institutions have $406K invested in BioRestorative Therapies in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital inflows, than outflows

Capital inflows: $74.5K | Capital outflows: $63.1K

0.17% more ownership

Funds ownership: 3.93% → 4.1% (+0.17%)

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$33.2K
2
UBS Group
UBS Group
Switzerland
+$24.1K
3
Morgan Stanley
Morgan Stanley
New York
+$15.5K
4
NDSI
Newman Dignan & Sheerar Inc
Rhode Island
+$1.55K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$34.8K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$22.2K
3
SG
StoneX Group
New York
-$3.68K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.52K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$898

BRTX Hedge Fund Activity: Q4 2024 in Review

14 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q4 2024, worth a combined $406K — down 14% from $472K a quarter earlier.

Fund positioning in BRTX was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 3 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $33.2K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $34.8K sold.

  • 14 institutional investors held BioRestorative Therapies (BRTX) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $406K of BioRestorative Therapies stock for Q4 2024, down 14% quarter-over-quarter.
  • 2 funds opened new BioRestorative Therapies positions in Q4 2024 and 2 closed out, a net change of 0 holders.
  • The largest BioRestorative Therapies buyer in Q4 2024 was Citadel Advisors, an estimated $33.2K added.
  • The largest BioRestorative Therapies seller in Q4 2024 was Renaissance Technologies, an estimated $34.8K sold.

Based on aggregated 13F filings for Q4 2024.